logo
Aromatic plant can fight colorectal cancer, say scientists

Aromatic plant can fight colorectal cancer, say scientists

Scientists endow a naturally growing plant with therapeutic properties that can effectively fight colorectal cancer.
SHARJAH, EMIRATE OF SHARJAH, UNITED ARAB EMIRATES, January 27, 2025 / EINPresswire.com / -- Scientists from the University of Sharjah have found that a naturally growing aromatic plant contains ingredients with the ability to treat colorectal cancer.
The plant is a common herb. It is scientifically known as Artemisia herba-alba. It grows naturally in North Africa and the Middle East where the inhabitants have traditionally been using it as medicine to treat bronchitis, diarrheas, hypertension and diabetes.
Artemisia herba-alba is popularly known by different appellations like common wormwood, white wormwood, or simply herba alba.
The news that it can be an effective weapon to fight colorectal cancer is reported in a study published in the peer-reviewed journal Food Science and Nutrition. (Original source URL: https://onlinelibrary.wiley.com/doi/full/10.1002/fsn3.4715)
'These results suggest that Artemisia herba-alba has great potential as a new tool in fighting CRC (colorectal cancer),' says Dr. Lara Bou Malhab. 'Artemisia herba-alba could be a promising natural ingredient for new cancer treatments based on (our study's) findings.'
Dr. Bou Malhab, the study's lead author, is a research associate at Sharjah University's Research Institute for Medical and Health Sciences. The plant material for the study included aerial parts of Artemisia herba-alba that were collected from southern Jordan in May 2021.
'[Co-author) Prof. M. Hudaib, an esteemed expert in Pharmacognosy and Phytochemistry at the University of Jordan's School of Pharmacy, conducted the botanical identification of these specimens,' the authors write. 'After collection, the aerial parts were air-dried at room temperature, and protected from direct sunlight to avoid deterioration of sensitive components.'
Once dried, the plant material was mechanically ground into fine powder 'with particles no larger than 0.5 mm. This preliminary step was done to enhance the effectiveness of the next extraction process, guaranteeing the highest possible amount of the extracted phytochemicals.'
The study finds that the extract contained many active compounds with properties capable of fighting colorectal cancer with various degrees of effectiveness. The findings show that the extract from Artemisia herba-alba stopped the growth of cancerous cells and caused them to die, regardless of specific genetic traits.
'It also disrupted the cell cycle and reduced the activity of proteins like Cyclin B1 and CDK1, which are crucial for cancer cell division. Additionally, it blocked the PI3K/AKT/mTOR pathway, which plays a major role in cancer development,' adds Dr. Bou Malhab.
'The current study underscores the extract's selective cytotoxicity against CRC cell lines, highlighting its potential to serve as a complementary treatment to existing cancer treatment with more efficacious and less harmful alternatives.
'Our findings highlight the immense potential of Artemisia herba-alba as a natural source for developing innovative therapies against colorectal cancer, addressing the urgent need for treatments with fewer side effects and greater efficacy.'
Colorectal cancer or CRC is the third most common cancer worldwide. It accounts for nearly 10% of all cancer cases. It is the second leading cause of cancer-related deaths. In 2020, it caused 1 million deaths with two million new cases reported in the same year. According to World Health Organization, CRC predominantly affects old individuals with most cases occurring in people aged 50 and above.
'Colorectal cancer (CRC) is a common and serious illness, making it essential to find new and better treatments,' emphasizes Dr. Bou Malhab.
The study could assume considerable significance if noted and adopted by big pharma as current traditional chemotherapy, used to treat colorectal cancer, faces challenges with cancerous cells becoming resistant to the drugs besides their harmful side effect.
'Which is why alternative solutions are needed. One plant, Artemisia herba-alba, known for its medicinal applications, was studied for its ability to fight CRC,' maintains Dr. Bou Malhab.' Researchers tested a methanol-based extract of this plant on eight different types of CRC cells, aiming to see how it affected cell survival, growth, and death, as well as its impact on a key cancer-related pathway.'
The study's findings emphasize Artemisia herba-alba's 'potential as an anticancer agent for CRC. [They] demonstrate its cytotoxic effects, ability to induce apoptosis, ability to arrest the cell cycle …, suggesting a wider therapeutic significance.'
As they conclude their study by recounting their findings, the scientists urge further research 'to elucidate the molecular mechanisms and clinical efficacy of Artemisia herba-alba in the context of cancer treatment.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tagomics awarded £860k grant for colorectal cancer diagnostic
Tagomics awarded £860k grant for colorectal cancer diagnostic

Yahoo

time13 hours ago

  • Yahoo

Tagomics awarded £860k grant for colorectal cancer diagnostic

Tagomics has been awarded £860,000 ($1.1m) from Innovate UK to develop a test for diagnosing early-stage colorectal cancer (CRC). The Cambridge, UK-based company said the money from the UK government innovation agency's Biomedical Catalyst programme would help fund a £1.2m project that is applying its Interlace multiomics workflow platform towards the detection of genetic and epigenetic mutations associated with CRC. This includes the development of new models for analysing patients' multiomic profiles to identify new disease biomarkers. Once the project concludes, a pilot study of the diagnostic test will be undertaken with the UK National Health Service (NHS). Led by Dr Arash Assadsangabi, consultant physician and gastroenterologist at Salford Royal NHS Foundation Trust, in collaboration with the Northern Care Alliance Research Collection biobank, the study will profile 250 patients suspected of having CRC to validate identified biomarkers and demonstrate multiomic profiling's efficacy in the early detection of the disease. Tagomics' chief scientific officer and co-founder, Dr Robert Neely said: 'We believe that the unique, information-rich dataset that Interlace provides us will be pivotal in detecting CRC at the earliest possible stages of development, enabling treatment of the cancer when it is most vulnerable to modern therapeutics, with the aim of dramatically improving patient outcomes.' Upon completion of the project, Tagomics will look to further expand the capabilities and applications of its Interlace platform with the support of Agilent Technologies, building on an established partnership that was key to the early development of the platform, Dr Neely added. The American Cancer Society estimates that there will be 107,320 new cases of colon cancer and 46,950 new cases of rectal cancer in 2025. According to GlobalData analysis, with early detection of CRC critical in reducing the disease's mortality rate, in vitro diagnostic (IVD) tests have a critical role to play in bridging the disease's screening gap, with company's such as Guardant Health at work on developing patient-first tests to create solutions that make patient care more accessible. Guardant's SHIELD test, which was approved by the US Food and Drug Administration (FDA) as a primary screening option for CRC in 2024, is intended to detect alterations in the blood associated with CRC. "Tagomics awarded £860k grant for colorectal cancer diagnostic" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Yahoo

time20 hours ago

  • Yahoo

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif., June 10, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company's 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world's most urgent challenges. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. The second leading cause of cancer-related deaths in the U.S., CRC has a 91 percent five-year survival rate if caught in early stages. Yet one out of three eligible adults in the U.S. (over 50 million people) do not complete the recommended screening in part because they find the available options—colonoscopy and stool tests—unpleasant or inconvenient. With Shield, individuals can be screened with a simple blood draw during a routine office visit, helping to detect more cancers early, when they are more treatable. "With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of people who delay their recommended screening for colorectal cancer," said AmirAli Talasaz, Guardant Health co-founder and co-CEO. "This latest honor for Shield recognizes the groundbreaking innovation created by our team at Guardant Health and the world-changing potential of the Shield blood test. By overcoming barriers with current screening methods, we can help increase the overall screening rate, find more cancers at an early stage, and give people more time free from cancer." A panel of Fast Company editors and reporters selected the winners from a pool of more than 1,500 entries and judged applications based on their impact, sustainability, design, creativity, scalability, and ability to improve society. This year's awards are featured on "The World Changing Ideas Awards have always been about showcasing the art of the possible," says Fast Company editor-in-chief Brendan Vaughan. "We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time." The Shield blood test was also named to TIME's list of the best inventions of 2024 and selected as a Grand Award Winner in Popular Science's Best of What's New 2024 (Health category). Shield is also the first blood test that is FDA approved for primary screening to be included in The National Comprehensive Cancer Network (NCCN) colorectal cancer (CRC) screening guidelines. Shield is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit About Shield Shield is a non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release. View source version on Contacts Investor Contact: Zarak Khurshidinvestors@ Media Contact: Michael Weistpress@ +1 317-371-0035

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening
Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

Business Wire

time20 hours ago

  • Business Wire

Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company's 2025 World Changing Ideas Awards. These annual awards recognize innovative companies and projects addressing the world's most urgent challenges. This latest honor for Shield recognizes the groundbreaking innovation created by our team at Guardant Health and the world-changing potential of the Shield blood test. Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. The second leading cause of cancer-related deaths in the U.S., CRC has a 91 percent five-year survival rate if caught in early stages. Yet one out of three eligible adults in the U.S. (over 50 million people) do not complete the recommended screening in part because they find the available options—colonoscopy and stool tests—unpleasant or inconvenient. With Shield, individuals can be screened with a simple blood draw during a routine office visit, helping to detect more cancers early, when they are more treatable. 'With a simple blood draw, Shield provides a more convenient and pleasant screening option for the millions of people who delay their recommended screening for colorectal cancer,' said AmirAli Talasaz, Guardant Health co-founder and co-CEO. 'This latest honor for Shield recognizes the groundbreaking innovation created by our team at Guardant Health and the world-changing potential of the Shield blood test. By overcoming barriers with current screening methods, we can help increase the overall screening rate, find more cancers at an early stage, and give people more time free from cancer.' A panel of Fast Company editors and reporters selected the winners from a pool of more than 1,500 entries and judged applications based on their impact, sustainability, design, creativity, scalability, and ability to improve society. This year's awards are featured on 'The World Changing Ideas Awards have always been about showcasing the art of the possible,' says Fast Company editor-in-chief Brendan Vaughan. 'We're proud to recognize the organizations and leaders that are making meaningful progress on the biggest issues of our time.' The Shield blood test was also named to TIME's list of the best inventions of 2024 and selected as a Grand Award Winner in Popular Science's Best of What's New 2024 (Health category). Shield is also the first blood test that is FDA approved for primary screening to be included in The National Comprehensive Cancer Network (NCCN) colorectal cancer (CRC) screening guidelines. Shield is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older and can be ordered by any prescribing healthcare provider. For more information, visit About Shield Shield is a non-invasive, blood-based screening test that detects alterations associated with colorectal cancer in the blood. It is intended as a screening test for individuals at average risk for the disease, age 45 or older, and is not intended for individuals at high risk for colorectal cancer. The Shield test can be considered in a manner similar to guideline-recommended non-invasive CRC screening options and can be completed during any healthcare visit. A positive Shield result raises concern for the presence of colorectal cancer or advanced adenoma and the patient should be referred for colonoscopy evaluation. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit and follow the company on LinkedIn, X (Twitter) and Facebook. Guardant Health Forward-Looking Statements This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store